Breaking News, Collaborations & Alliances

Ricoh Licenses CRISPR/Cas9 Tech to ERS Genomics for Drug Discovery

CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model.

Author Image

By: Charlie Sternberg

Associate Editor

Ricoh Company Ltd. has entered a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited for access to the CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.   CRISPR/Cas9 is designed to modify targeted genome sequences with ease. The technology is an essential tool in drug discovery research and finds application across various fields.   The goal of the agreement is to predict the mechanism of action of candidate drugs for patients with varied ge...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters